The U.S. government is pushing Covid-19 vaccine boosters for 16- and 17-year-olds without supporting clinical data. A large Israeli population study, published in the New England Journal of Medicine earlier this month, found that the risk of Covid death in people under 30 with two vaccine shots was zero.
Booster mandates for healthy young people, which some colleges are imposing, will cause medical harm for the sake of transient reductions in mild and asymptomatic infections. In a study of 438,511 males 16 to 24, 56 developed myocarditis after their second Pfizer dose (or 1 in 7,830, at least seven times the usual rate). True, most cases were mild, but in the broader group of 136 people (including older and female patients) who developed myocarditis after the vaccine, seven had a “complicated course,” and one 22-year-old died. Moderna’s vaccine carries an even higher rate of heart complications, which is why some European countries have restricted it for people under 30. But in the U.S., the Food and Drug Administration and the Centers for Disease Control and Prevention indiscriminately push for boosters for all young people.
Those recommendations came over the objections of the agencies’ own experts. The last vote by FDA advisers, in September, rejected the proposal 16-2. FDA leaders revisited the proposal in November and simply bypassed the experts. So did the CDC, whose advisers had rejected boosters for people not at high risk. Two top FDA scientists, including the head of the agency’s vaccine efforts, quit around the time of the September vote over White House pressure to authorize boosters for all. They wrote in detail about their concerns.